Matthew Calkins
Analyst · Morgan Stanley. Please proceed with your question
Thank you, Staci. Thank you all for joining us today. In the third quarter of 2017, Appian grew subscription revenue 35% year-over-year to $20.7 million. Our non-GAAP loss from operations was $4.9 million, an improvement from a loss of $6.2 million in the prior year quarter. Our subscription revenue retention was 122% in Q3 increasing again as it has each quarter this year. All three of these figures are ahead of our guidance. Our professional services revenue was $22 million, that sequential growth of 4% and our non-GAAP professional services gross margin was 36%. Appian as a horizontal platform sold in an increasingly vertical fashion. In recent years, our primary verticals have been financial services, pharmaceuticals and federal government. Consequently we invested in sales and marketing to enhance our expertise in these sectors resulting in increased revenue and more customers. Lately, we are making investments in other industries. Through the third quarter, healthcare subscription revenue nearly tripled versus the prior year period. Year-to-date we’ve closed about as much new named healthcare business as we did new name financial services business in all of 2016. Additionally, the average deal size for new healthcare payers, rivals, new financial services and pharma deal sizes putting it in line with Appian’s strongest sectors. In Q3, we accelerated our growth in healthcare by signing top five healthcare payer. This organization produced a multimillion dollar five year agreement to replace their pre-authorization management solution, which allows doctors to get pre-approval for medical procedures on behalf of patients. As we discussed in our IPO filing, another healthcare payer, HCSC reports $10 million of annual savings with a similar Appian application. Deciding factors in our recent win included implementation speed, integration capabilities and of course demonstrated ROI. With this new customer, three of the top five healthcare payers now use Appian to perform core business functions, such as approving life saving medical procedures, introducing new products to the market and automating clinical operations and end-to-end care management for their more than 70 million combined members. After we signed new customers, our industry expertise helped them gain value for our platform leading to follow on purchases. In the third quarter, a coupled expansion deals demonstrates the strength of our land and expense strategy. Over the past three years, the major bank in the Western United States used Appian to build more than a dozen mission critical applications across their commercial retail and wealth divisions. They increased efficiency in these areas by 42% by removing obsolete tasks and reducing thousands of hours of unnecessary work each year. In Q3, the bank made an additional multimillion dollar five year investment to expand Appian across their middle market division. These expanded licenses will support the know-your-customer application which allows the bank to verify the identity of customers before they open accounts. Secondly, one of the world’s top biotechnology firms extended their initial purchase with a $1.2 million add-on. They adopted Appian only last March to automate their external stakeholder engagement process which brings together data from many legacy systems to ensure their compliance with regulatory requirements. Their new licenses purchased only six months after their initial buy will allow them to roll out this application more broadly. Appian’s partner Ecosystem including technology partners influenced about half of our new customer deals globally in Q3. This has been true for five quarters running. Additionally, in the first three quarters of 2017 the value of partner sourced deals grew four and one half times compared to the same period in 2016, and new logo acquisition grew two and one half times year-over-year. Our key technology partnerships with Microsoft, Blue Prism and MuleSoft all goes through fruit in Q3. This quarter, Appian announced that customers can now run our platform on the Microsoft Azure. Cloud agnosticism is important to many companies who want to run in the cloud now or in the future but wish to remain flexible and do not want to be locked into one specific cloud vendor. Two months after announcing a new robotic process automatic capability called Appian RPA with Blue Prism, we sold it for the first time to the department of health and human services. HHS’s program support center is the largest multifunction shared service provider since our government. Their existing processes take months to reconcile and to finalize procurement acquisitions. They chose Appian RPA with Blue Prism because of the combination of our platform along with Blue Prism’s technology, it allows for more powerful automation with legacy systems and faster implementation. MuleSoft, our partner MuleSoft which provides an integration platform help us close a $1 million deal with a global manufacturer of physical infrastructure equipment. This new Appian customer wanted to replace their existing BPM vendor happens to be one of our largest competitors because they desired a modern platform that could be used to quickly build critical business applications. Appian’s integration with MuleSoft allows our mutual customers to give users the information they need to be effective. Our overseas partner program was particularly successful. Partners influenced a just proportionate number of our international Q3 deals. Notably, PwC led us into a significant expansion with the top five banks in Spain, and other partners brought us million dollar deals with two new customers and Austrian banking group and an Australian Federal Agency. In conclusion, we continue to evolve our technology. We expand within our customer base and we add new marquee [Ph] customers. Appian’s steady, Q3 results give further evidence that we are disrupting and reinventing one of the biggest areas of IT spend that of customs software. With that, let me turn the call over to Mark to walk you through the financials. Mark?